Skip to main content

Bioventus Inc.

corporate_fare Company Profile

Bioventus Inc.

BVS·NASDAQ·Industrial Applications And Services·CIK 0001665988

Bioventus Inc. is a global medical device company that helps patients recover from musculoskeletal challenges and pain. The company operates through two reporting segments: U.S., which generated 88% of total net sales, and International, which generated 12% of total net sales during the fiscal year ended December 31, 2025. Its products are organized into three businesses based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. The Pain Treatments business includes Knee Osteoarthritis (KOA) products, which are hyaluronic acid (HA) injections for pain relief, and the XCELL Platelet-Rich Plasma (PRP) system distributed in the U.S. This segment also includes Peripheral Nerve Stimulation (PNS) products for acute, temporary, and chronic pain. The Surgical Solutions business offers Ultrasonics for precision bone resection in degenerative spine conditions, spinal deformities, brain tumors, and pathologies of the liver and other organs. It also includes Bone Graft Substitutes (BGS) products that aid bone fusion after surgery. The Restorative Therapies business focuses on Fracture Care, providing low-intensity pulse ultrasound for bone fractures that do not heal with traditional methods.

Bioventus Inc. (NASDAQ:BVS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for BVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-05, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BVS spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Bioventus Misses Q2 Revenue, Launches Strategic Review, and Books Tax Benefit
  • Bioventus Q2 Revenue Misses, Launches Strategic Review Including Potential Sale
  • Bioventus Launches Strategic Review Including Potential Sale After Q2 Beat; Reaffirms 2026 Guidance
  • Law Firm Investigates Bioventus Insiders for Fiduciary Duty Breach
  • Bioventus Reports Strong Q1 Profitability, Exceeds Revenue Estimates, and Reduces Debt

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$568.09M
Net Income
$22.73M
Diluted EPS
$0.33
Op. Cash Flow
$74.67M
Free Cash Flow
$72.11M
Gross Profit
$388.16M
Operating Income
$53.98M
Cash & Equivalents
$51.24M
Total Debt
$293.95M
Debt / Equity
1.60×
Net Margin
4.0%
Shares Outstanding
66.62M sh
Source: 10-K · filed 2026-03-05 · accession 0001665988-26-000011

Short Interest & Short Volume

5.73 days to cover

FINRA reported short interest of 2,930,690 shares in BVS as of the September 15, 2026 settlement, a 13.6% increase from the prior period — about 5.7 days to cover at its recent average daily volume. On October 2, 2026, 70.0% of BVS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,930,690 shares as of September 15, 2026
Change vs prior period▲ 13.6%
Days to cover5.73 at avg daily volume of 511,273
Daily short volume (FINRA facilities)70.0% of 105,677 shares on October 2, 2026
5-day average short volume76.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$13.13
52-week range · as of 2026-08-05 $5.81 – $14
Market cap
$1.1B
Volume
362.4K (0.7× avg)
3-mo avg 507K
Live data · 2026-10-05 04:24 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed BVS - Latest Insights

BVS
Aug 05, 2026, 7:43 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.12
Real-time Price: $13.13 info
Change: +$1.01 (+8%) info
Market Cap: $1.104B info
BVS
Aug 05, 2026, 7:41 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $11.21
Real-time Price: $13.13 info
Change: +$1.92 (+17%) info
Market Cap: $1.104B info
BVS
Aug 05, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.13
Real-time Price: $13.13 info
Change: +$1.00 (+8%) info
Market Cap: $1.104B info
BVS
Jul 03, 2026, 12:24 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $10.88
Real-time Price: $13.13 info
Change: +$2.25 (+21%) info
Market Cap: $1.104B info
BVS
May 06, 2026, 7:48 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.99
Real-time Price: $13.13 info
Change: +$2.14 (+19%) info
Market Cap: $1.104B info
BVS
May 06, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.80
Real-time Price: $13.13 info
Change: +$2.33 (+22%) info
Market Cap: $1.104B info
BVS
May 06, 2026, 7:30 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.67
Real-time Price: $13.13 info
Change: +$2.46 (+23%) info
Market Cap: $1.104B info
BVS
Apr 22, 2026, 7:51 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $9.64
Real-time Price: $13.13 info
Change: +$3.49 (+36%) info
Market Cap: $1.104B info
BVS
Mar 05, 2026, 7:37 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $13.13 info
Change: +$3.89 (+42%) info
Market Cap: $1.104B info
BVS
Mar 05, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $13.13 info
Change: +$3.89 (+42%) info
Market Cap: $1.104B info
BVS
Mar 05, 2026, 7:04 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.16
Real-time Price: $13.13 info
Change: +$3.97 (+43%) info
Market Cap: $1.104B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets